AbbVie and Genmab’s epcoritamab has shown promise as part of a combination treatment for relapsed or refractory follicular ...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look ...

Over the past decade, AbbVie's shares have increased by 353.3%, or 16.3% annually, with dividends reinvested. That's ...

The expansion is part of AbbVie’s larger $10 billion commitment to U.S. investment in the face of Trump’s tariff threats.

AbbVie (NYSE: ABBV) announced today that it has completed its acquisition of Capstan Therapeutics. With the completion of the acquisition, Capstan is now a part of AbbVie.

Construction on the site will begin in the fall and is expected to be finished by 2027. North Chicago is already home to ...

AbbVie (ABBV) announced a $195 million investment in its North Chicago manufacturing facility to boost domestic API ...

The project aims to enhance AbbVie’s chemical synthesis capacity to support next-generation neuroscience, immunology, and ...

AbbVie will invest $195M to expand API manufacturing at its North Chicago plant, boosting U.S. pharmaceutical innovation, ...

AbbVie is investing $195m to strengthen domestic API production, with the expansion of its manufacturing plant in North ...

AbbVie, a global leader in life sciences, announced Tuesday the company’s is investing $195 million to expand its North ...

NORTH CHICAGO Governor JB Pritzker, AbbVie, and the Illinois Department of Commerce and Economic Opportunity (DCEO) today ...